AMOEBA (EPA:ALMIB) - AMOEBA announces a postponement of the conclusion of the evaluation by Malta of the biocide active substance dossier

Transparency directive : regulatory news

05/07/2021 17:45

PRESS RELEASE

Amoeba announces a postponement of the conclusion of the evaluation by Malta
of the biocide active substance dossier

Chassieu (France), July 5th, 2021 - 5:45 p.m. - AMOÉBA (FR0011051598 - ALMIB),
producer of a biological biocide capable of eliminating bacterial risk in water
and human wounds, and of a biocontrol product for plant protection, still in
the development phase, announces that it has received, on June 24th, 2021, a
final set of questions from the Maltese Authority which is evaluating the
biocidal active substance dossier.

As a reminder, in its press release dated April 6th, 2021, specifying the
timetable for the biocidal and phytosanitary regulatory dossiers, the Company
estimated that the evaluation report of its "Biocide" dossier by the Maltese
Authority could be available by mid-2021.

Considering the time needed to submit the response file, as well as the time
needed for the assessment of the response file, the Maltese Authority has
committed to finalise the assessment report in the 4th quarter of 2021.

The Company has decided to take advantage of this new series of questions to
enrich its dossier by also submitting the results of a laboratory study
currently under finalization, based on the European standard EN 13623(1), which
demonstrates an abatement of more than 99% of the legionella level over 96
hours. This efficacy study complements the efficacy data already submitted,
strengthening the demonstration of the efficacy of the active substance in
continuous injection.

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on Euronext Growth. The Company is
a member of the BPIfrance Excellence network and is eligible for the PEA-PME
SME equity savings plan setup. More information on www.amoeba-nature.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,
" Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

(1) EN 13623 (2020) Chemical disinfectants and antiseptics. Quantitative
suspension test for the evaluation of bactericidal activity against Legionella
of chemical disinfectants for aqueous systems. Test method and requirements
(phase 2, step 1)

Contacts: Amoéba
Valérie FILIATRE
Directeur Général Adjoint
+33 4 26 69 16 00
v.filiatre@amoeba-nature.com

Calyptus
Relations investisseurs & Presse
Grégory BOSSON / Mathieu CALLEUX
+33 1 53 65 37 90 /91
amoeba@calyptus.net

Disclaimer

This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the Universal
Registration Document of AMOEBA filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) on April 12, 2021 under number
D21-0289 (a copy of which is available on www.amoeba-nature.com). The
forward-looking statements contained in this press release are also subject to
risks not yet known to AMOEBA or not currently considered material by AMOEBA.
The occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of AMOEBA to be materially
different from such forward-looking statements.

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU
Société Anonyme au capital de 341 109,20 EUR
RCS Lyon 523 877 215

Tel: +33 (0)4 26 69 16 00 ? Email: contact@amoeba-nature.com
Linkedin: @amoeba-nature ? Twitter: @AmoebaNature
www.amoeba-nature.com

AMOEBA's latest news

02/05/2024 18:00

AMOEBA (EPA:ALMIB) - AMOEBA announces a postponement of the conclusion of the evaluation by Malta of the biocide active substance dossier

Transparency directive : regulatory news

AMOEBA's latest news

Other stories